A recent study has found a concerning link between the use of semaglutide-based GLP-1 drugs such as Ozempic and suicidal ideation, as well as the concurrent use of antidepressants or benzodiazepines. National health authorities have not previously reported this connection, but further research is ongoing. Semaglutide medications have gained popularity as weight loss drugs, with Wegovy and other similar drugs receiving FDA approval for this purpose. On the other hand, liraglutide GLP-1 drugs like Saxenda have not been associated with increased suicidal ideation when combined with antidepressants.
Experts have raised concerns about the potential for GLP-1 drugs to trigger suicidal thoughts following reports from Iceland and the FDA. However, the FDA and EMA conducted investigations and found no definitive link between the drugs and suicidal ideation. A study published in January 2024 by the National Institutes of Health even found that individuals taking GLP-1 drugs had lower rates of suicidal ideation compared to others. The latest study, published in JAMA Network Open, adds a new perspective by identifying a disproportionate relationship between semaglutide medications and suicidal ideation in individuals also taking antidepressants and benzodiazepines.
Lead author Georgios Schoretsanitis emphasized that the study’s findings of disproportionality should not be taken as evidence of a causal relationship or severity. It remains unclear how strong the association is and whether GLP-1 drugs directly contribute to suicidal ideation. Mir Ali, a board-certified bariatric surgeon, highlighted the challenge of linking GLP-1 medications and suicidal ideation due to the rarity of such occurrences. Separating pre-existing mental health issues from those potentially induced by the medication is also a complex task.
Ian Douglas, a professor of pharmacoepidemiology, pointed out the difficulty in assessing the impact of GLP-1 drugs on mental health due to confounding factors. While the NIH study does not definitively demonstrate that GLP-1 agonists prevent mental health issues, it does not indicate harm either. However, Douglas questioned the methodology of the new study, suggesting that spontaneous reports of adverse drug reactions may not be the most suitable resource for testing the hypothesis. Similarly, Ali expressed concerns about disproportionality analysis as a quick and inexpensive method for assessing group representation in adverse outcomes.
In response to the study’s findings, Schoretsanitis recommended that physicians prescribing semaglutide drugs inform patients about the associated risks, assess their psychiatric history, and evaluate their mental state before initiating treatment. In cases of persistent suicidal ideation or other mental health disorders, involving specialists such as psychiatrists and psychologists for evaluation is advised. Off-label use of semaglutide without medical supervision is strongly discouraged, as the proper monitoring of side effects and treatment outcomes is essential. Overall, there is a crucial need for caution and responsibility in prescribing and monitoring GLP-1 medications to ensure patient safety and well-being.
